Aidi Pharma Receives Approval for Phase III Trial of ADC118 Tablet

36Kr reports that Aidi Pharma announced the company and its wholly-owned subsidiary have received the "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration, approving the development of a Phase III clinical trial for ADC118 tablets, a novel Class I drug in the field of anti-HIV. The drug is a self-developed triple-combination formulation consisting of ACC017, an HIV integrase chain transfer inhibitor, emtricitabine, and cobicistat/tenofovir alafenamide (TAF), intended for the treatment of adults infected with HIV-1.